Who
Erin Parsons
Director
Company insider
Files Form 4 as: Director, Kiora Pharmaceuticals; Director, Alimera Sciences.
In numbers
- Trades disclosed
- 15
- Buys
- 1
- Sells
- 0
- Bought
- $26K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 30 Nov 2021
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 1 Apr 2025filed 2 Apr 2025 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 16 Sep 2024filed 18 Sep 2024 | Alimera Sciencesoption or derivative | SEC FORM 4 Code D | —50,000 | filing |
| 16 Sep 2024filed 18 Sep 2024 | Alimera Sciencesoption or derivative | SEC FORM 4 Code D | —6,000 | filing |
| 16 Sep 2024filed 18 Sep 2024 | Alimera Sciencesoption or derivative | SEC FORM 4 Code D | —3,255 | filing |
| 1 Jul 2024filed 3 Jul 2024 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,778 at $0.00 | filing |
| 13 Jun 2024filed 13 Jun 2024 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $26K5,260 at $4.88 | filing |
| 2 Oct 2023filed 4 Oct 2023 | Alimera Sciencesoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 29 Sep 2023filed 3 Oct 2023 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 3 Mar 2023filed 7 Mar 2023 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 4 Jan 2023filed 6 Jan 2023 | Alimera Sciencesoption or derivative | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 1 Feb 2022filed 3 Feb 2022 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 1 Feb 2022filed 3 Feb 2022 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 30 Nov 2021filed 2 Dec 2021 | Alimera Sciencesoption or derivative | SEC FORM 4 Code A | —3,255 at $0.00 | filing |
News
Supernus Pharmaceuticals (NASDAQ:SUPN) vs. Kiora Pharmaceuticals (NASDAQ:KPRX) Critical SurveyKPRX · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Erin Parsons; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.